康芝药业：目前宏氏投资已给公司支付1.1亿元履约准备金

Core Viewpoint - The company is actively overseeing the share repurchase commitment by its major shareholder, emphasizing the protection of shareholder rights and compliance with regulatory requirements [2] Group 1 - The company has received a performance deposit of 110 million yuan from Hongshi Investment for the share repurchase [2] - The company is committed to urging the major shareholder to fulfill their obligations regarding the share repurchase [2] - The company will disclose relevant progress in accordance with regulatory requirements [2]